ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

ADARx Pharmaceuticals is seeking a valuation of ​up to $1.74 billion in its ‌U.S. initial public offering, the company said on Monday, as investor appetite for ​biotech listings strengthens.